Immunosuppressants Market by Drug class (Corticosteroids, Monoclonal Antibodies (mAbs), Calcineurin Inhibitors, mTOR Inhibitors, Anti-Proliferative Agents, and Others), Indication (Organ Transplantation, Autoimmune Disorders, and Non-Autoimmune Inflammatory Diseases), and Distribution channel (Hospital pharmacies, Retail pharmacies and Online pharmacies): Global Opportunity Analysis and Industry Forecast, 20192026
- Published Date: 2020-10-06
- Report ID: 1418
- Pages: 165
-
Format:
The global immunosuppressants market was valued at $13,890.0 million in 2018 and is expected to reach $42,511.37 million by 2026, registering a CAGR of 14.7% from 2019 to 2026. Immunosuppressants suppress the immune response or agents after organ transplantation or grafting procedures. After an organ transplantation, recipients body produces certain immune response against it as it considers the organ as an antigen that may harm the body. These immunosuppressants help in combating hyper immune response produced by bodys immune cells. These drugs are a crucial part of organ transplantation procedure as it prevents the body from serious damages.
Increase in incidence of autoimmune disorders such as arthritis, multiple sclerosis, and alopecia areata is the major factor that drives the market growth. In addition, surge in organ transplant procedures such as kidney transplant and liver transplant due to rise in incidence of organ failure further propels the market growth. For instance, as per the U.S. Government Information on Organ Donation and Transplantation, 36,528 organ transplants were performed in 2018 in the country. However, dearth of availability of organ donors and high cost of transplantation as well as immunosuppressant drugs are the limitations for the growth of this market. In addition, side effects of these drugs are expected to hamper the market growth. One of the major side effects of these drugs, especially, corticosteroids is osteoporosis. It is the condition in which density of bones is decreased, increasing the risk of fractures. Any bone in the body can be affected; however, fractures are most commonly seen in the hip, spine, or wrist. On the contrary, increase in use of tissue engineering for generation of implants provides growth opportunities for this market. In addition, rise in disposable income in developing economies, surge in awareness among individuals towards organ donation is anticipated to create lucrative opportunities in the near future.
The market is segmented on the basis of drug class, indication, distribution channel, and region. By drug class, it is divided into corticosteroids, monoclonal antibodies, calcineurin inhibitors, mTOR inhibitors, anti-proliferative agents, and others. On the basis of indication, it is categorized into organ transplantation, autoimmune disorders, and non-autoimmune inflammatory diseases. By distribution channel, it is classified into hospital pharmacies, retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
Comprehensive analysis of four major regions is provided to determine the prevailing opportunities.
Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Drug Class
Corticosteroids
Monoclonal Antibodies (mAbs)
Calcineurin Inhibitors
mTOR Inhibitors
Anti-Proliferative Agents
Others
By Indication
Organ Transplantation
Autoimmune Disorders
Non-Autoimmune Inflammatory Diseases
By Distribution Channel
Hospital pharmacies
Retail pharmacies
Online pharmacies
By Region
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
Asia Pacific
o Japan
o China
o India
o Australia
o Rest of Asia-Pacific
LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
KEY PLAYERS
Astellas Pharma, Inc.
Bristol Myers Squibb
AbbVie Inc.
GlaxoSmithKline Plc.
Intas Pharmaceuticals Ltd.
Johnson & Johnson
Mylan Laboratories Inc
Novartis AG
Pfizer Inc.
Sanofi S.A
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models
Chapter 2: Executive Summary
2.1. Key Findings of The Study
2.2. Cxo Perspective
Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.3. PorterS Five Forces Analysis
3.3.1. Moderate Bargaining Power of Buyers
3.3.2. Low Bargaining Power of Suppliers
3.3.3. Moderate Threat of Substitutes
3.3.4. Low Threat of New Entrants
3.3.5. Moderate Competitive Rivalry
3.4. Top Player Positioning
3.5. Market Dynamics
3.5.1. Drivers
3.5.1.1. Surge In Autoimmune Disorders
3.5.1.2. Increase In Demand For Organ Transplantation
3.5.2. Restraint
3.5.2.1. Lack of Awareness Towards Organ Transplantation
3.5.3. Opportunity
3.5.3.1. Various Growth Opportunities In Emerging Economies
Chapter 4: Immunosuppressant Market, By Indication
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Organ Transplantation
4.2.1. Key Market Trends And Opportunities
4.2.2. Market Size And Forecast
4.2.3. Market Share Analysis, By Country
4.3. Autoimmune Disorders
4.3.1. Key Market Trends And Growth Opportunities
4.3.2. Market Size And Forecast
4.3.3. Market Share Analysis, By Country
4.4. Other Diseases
4.4.1. Key Market Trends And Opportunities
4.4.2. Market Size And Forecast
4.4.3. Market Share Analysis, By Country
Chapter 5: Immunosuppressant Market, By Drug Class
5.1. Overview
5.1.1. Market Size And Forecast
5.2. Calcineurin Inhibitors
5.2.1. Market Size And Forecast
5.2.2. Market Share Analysis, By Country
5.3. Corticosteroids
5.3.1. Market Size And Forecast
5.3.2. Market Share Analysis, By Country
5.4. Monoclonal Antibodies (Mabs)
5.4.1. Market Size And Forecast
5.4.2. Market Share Analysis, By Country
5.5. Mtor Inhibitors
5.5.1. Market Size And Forecast
5.5.2. Market Share Analysis, By Country
5.6. Other Immunosuppressants
5.6.1. Market Size And Forecast
5.6.2. Market Share Analysis, By Country
Chapter 6: Immunosuppressants Market, By Distribution Channel
6.1. Overview
6.1.1. Market Size And Forecast
6.2. Hospital Pharmacies
6.2.1. Market Size And Forecast
6.2.2. Market Share Analysis, By Country
6.3. Retail Pharmacies
6.3.1. Market Size And Forecast
6.3.2. Market Share Analysis, By Country
6.4. Online Pharmacy
6.4.1. Market Size And Forecast
6.4.2. Market Share Analysis, By Country
Chapter 7: Immunosuppressant Market, By Region
7.1. Overview
7.1.1. Market Size And Forecast
7.2. North America
7.2.1. Key Market Trends And Opportunities
7.2.2. Market Size And Forecast, By Country
7.2.3. Market Size And Forecast, By Indication
7.2.4. Market Size And Forecast, By Drug Class
7.2.5. Market Size And Forecast, By Distribution Channel
7.2.6. U.S.
7.2.6.1. U.S. Market Size And Forecast, By Indication
7.2.6.2. U.S. Market Size And Forecast, By Drug Class
7.2.6.3. U.S. Market Size And Forecast, By Distribution Channel
7.2.7. Canada
7.2.7.1. Canada Market Size And Forecast, By Indication
7.2.7.2. Canada Market Size And Forecast, By Drug Class
7.2.7.3. Canada Market Size And Forecast, By Distribution Channel
7.2.8. Mexico
7.2.8.1. Mexico Market Size And Forecast, By Indication
7.2.8.2. Mexico Market Size And Forecast, By Drug Class
7.2.8.3. Mexico Market Size And Forecast, By Distribution Channel
7.3. Europe
7.3.1. Key Growth Factors And Opportunities
7.3.2. Market Size And Forecast, By Country
7.3.3. Market Size And Forecast, By Indication
7.3.4. Market Size And Forecast, By Drug Class
7.3.5. Market Size And Forecast, By Distribution Channel
7.3.6. Germany
7.3.6.1. Germany Market Size And Forecast, By Indication
7.3.6.2. Germany Market Size And Forecast, By Drug Class
7.3.6.3. Germany Market Size And Forecast, By Distribution Channel
7.3.7. France
7.3.7.1. France Market Size And Forecast, By Indication
7.3.7.2. France Market Size And Forecast, By Drug Class
7.3.7.3. France Market Size And Forecast, By Distribution Channel
7.3.8. Uk
7.3.8.1. Uk Market Size And Forecast, By Indication
7.3.8.2. Uk Market Size And Forecast, By Drug Class
7.3.8.3. Uk Market Size And Forecast, By Distribution Channel
7.3.9. Italy
7.3.9.1. Italy Market Size And Forecast, By Indication
7.3.9.2. Italy Market Size And Forecast, By Drug Class
7.3.9.3. Italy Market Size And Forecast, By Distribution Channel
7.3.10. Rest of Europe
7.3.10.1. Rest of Europe Market Size And Forecast, By Indication
7.3.10.2. Rest of Europe Market Size And Forecast, By Drug Class
7.3.10.3. Rest of Europe Market Size And Forecast, By Distribution Channel
7.4. Asia-Pacific
7.4.1. Key Growth Factors And Opportunities.
7.4.2. Market Size And Forecast, By Country
7.4.3. Market Size And Forecast, By Indication
7.4.4. Market Size And Forecast, By Drug Class
7.4.5. Market Size And Forecast, By Distribution Channel
7.4.6. Japan
7.4.6.1. Japan Market Size And Forecast, By Indication
7.4.6.2. Japan Market Size And Forecast, By Drug Class
7.4.6.3. Japan Market Size And Forecast, By Distribution Channel
7.4.7. China
7.4.7.1. China Market Size And Forecast, By Indication
7.4.7.2. China Market Size And Forecast, By Drug Class
7.4.7.3. China Market Size And Forecast, By Distribution Channel
7.4.8. India
7.4.8.1. India Market Size And Forecast, By Indication
7.4.8.2. India Market Size And Forecast, By Drug Class
7.4.8.3. India Market Size And Forecast, By Distribution Channel
7.4.9. Australia
7.4.9.1. Australia Market Size And Forecast By Indication
7.4.9.2. Australia Market Size And Forecast, By Drug Class
7.4.9.3. Australia Market Size And Forecast, By Distribution Channel
7.4.10. Rest of Asia-Pacific
7.4.10.1. Rest of Asia-Pacific Market Size And Forecast By Indication
7.4.10.2. Rest of Asia-Pacific Market Size And Forecast, By Drug Class
7.4.10.3. Rest of Asia-Pacific Market Size And Forecast, By Distribution Channel
7.5. Lamea
7.5.1. Key Growth Factors And Opportunities
7.5.2. Market Size And Forecast, By Country
7.5.3. Market Size And Forecast, By Indication
7.5.4. Market Size And Forecast, By Drug Class
7.5.5. Market Size And Forecast, By Distribution Channel
7.5.6. Brazil
7.5.6.1. Brazil Market Size And Forecast, By Indication
7.5.6.2. Brazil Market Size And Forecast, By Drug Class
7.5.6.3. Brazil Market Size And Forecast, By Distribution Channel
7.5.7. Saudi Arabia
7.5.7.1. Saudi Arabia Market Size And Forecast, By Indication
7.5.7.2. Saudi Arabia Market Size And Forecast, By Drug Class
7.5.7.3. Saudi Arabia Market Size And Forecast, By Distribution Channel
7.5.8. South Africa
7.5.8.1. South Africa Market Size And Forecast, By Indication
7.5.8.2. South Africa Market Size And Forecast, By Drug Class
7.5.8.3. South Africa Market Size And Forecast, By Distribution Channel
7.5.9. Rest of Lamea
7.5.9.1. Rest of Lamea Market Size And Forecast, By Indication
7.5.9.2. Rest of Lamea Market Size And Forecast, By Drug Class
7.5.9.3. Rest of Lamea Market Size And Forecast, By Distribution Channel
Chapter 8: Company Profiles
8.1. Abbvie Inc.
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance
8.1.6. Key Strategic Moves And Developments
8.2. Astellas Pharma Inc.
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio
8.2.5. Business Performance
8.3. Bristol-Myers Squibb Company
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Business Performance
8.3.6. Key Strategic Moves And Developments
8.4. Glaxosmithkline Plc.
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Business Performance
8.4.6. Key Strategic Moves And Developments
8.5. Intas Pharmaceuticals Ltd. (Accord Healthcare Ltd.)
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance
8.6. Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance
8.6.6. Key Strategic Moves And Developments
8.7. Mylan N.V.
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.7.5. Business Performance
8.7.6. Key Strategic Moves And Developments
8.8. Novartis International Ag (Sandoz)
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio
8.8.5. Business Performance
8.8.6. Key Strategic Moves And Developments
8.9. Pfizer Inc.
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.9.5. Business Performance
8.9.6. Key Strategic Moves And Developments
8.10. Sanofi S.A.
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance
8.10.6. Key Strategic Moves And Developments
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
